Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Incoming students: Register for orientation excursions
- Attend information sessions on applying for Social Security
- Faculty, grad students invited to submit Freedman Center for Digital Scholarship Colloquium proposals by July 31
- Researchers find potential pathway to fight infection
- Law’s Andrew Pollis discusses law enforcement agreement in Flying Pilot J fraud case